Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Engineered Probiotic Bacteria Successfully Attack Tumors in Mouse Models
Researchers engineered probiotic bacteria to deliver anti-cancer drugs directly to tumors, showing promising targeted therapy results in preclinical models.
AstraZeneca’s Imfinzi Gets EU Approval for Early Gastric & GEJ Cancers
AstraZeneca's Imfinzi, combined with FLOT chemotherapy, receives EU approval for treating adult patients with resectable early gastric and GEJ cancers.
FDA Grants Fast Track to Argo Biopharma's BW-20805 siRNA Therapy for HAE
Argo Biopharma receives FDA Fast Track Designation for BW-20805, a novel siRNA therapy targeting PKK for the prevention of hereditary angioedema attacks.
New CAR-NKT Immunotherapy Destroys Endometrial Cancer in Preclinical Tests
UCLA researchers developed an off-the-shelf CAR-NKT immunotherapy that safely detects and destroys aggressive endometrial cancer in preclinical studies.
New Liquid Biopsy Tech: cf-EpiTracing Detects Disease from a Blood Drop
Peking University's cf-EpiTracing liquid biopsy platform detects and traces diseases, like cancer, from a single drop of blood with over 92% accuracy.
New Nanomedicine Gel by BITS Pilani for Rheumatoid Arthritis Treatment
BITS Pilani researchers develop a smart nanomedicine-based topical gel showing promising preclinical results for rheumatoid arthritis treatment and relief.
Parkinson's Research Reaches Pivotal Stage: New Models & Funding Barriers
Parkinson's disease research hits a pivotal point with new iPSC models, yet funding challenges and outdated trials slow development.
UCB’s Bimzelx Bests Skyrizi in Phase III PsA Study, Analysts Skeptical
UCB’s Bimzelx showed superiority over AbbVie’s Skyrizi in a Phase III psoriatic arthritis study, though analysts doubt a major impact on drug sales.
MHRA Approves Sun Pharma's Leqselvi for Severe Alopecia Areata in Adults
The MHRA has approved Sun Pharma's Leqselvi (deuruxolitinib) as a new treatment for adults with severe alopecia areata, showing strong hair regrowth results.
Iovance Announces Positive Data for Lifileucel TIL Therapy in Sarcomas
Iovance Biotherapeutics announces positive early data for its lifileucel TIL cell therapy in patients with advanced soft tissue sarcomas, showing a 50% ORR.
HeartWorks Advances New Model for Preclinical Biomedical Innovation in Wisconsin
HeartWorks is developing a preclinical biomedical innovation hub in Wisconsin to accelerate cardiovascular solutions and support early-stage MedTech startups.
Redx Achieves FDA Fast Track Designation for Crohn’s Disease Drug RXC008
Redx Pharma receives FDA Fast Track Designation for RXC008, a novel pan-ROCK inhibitor for fibrostenotic Crohn’s disease. Phase 2 trials begin this year.
1
2
3
4
5
6
7
